- Home
- RNAC vs FHTX Comparison
RNAC vs FHTX Comparison
Compare RNAC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- FHTX
- Stock Information
- Founded
- RNAC 2007
- FHTX 2015
- Country
- RNAC United States
- FHTX United States
- Employees
- RNAC N/A
- FHTX N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- RNAC Health Care
- FHTX Health Care
- Exchange
- RNAC Nasdaq
- FHTX Nasdaq
- Market Cap
- RNAC 472.7M
- FHTX 513.7M
- IPO Year
- RNAC 2016
- FHTX 2020
- Fundamental
- Price
- RNAC $17.33
- FHTX $8.01
- Analyst Decision
- RNAC Strong Buy
- FHTX Strong Buy
- Analyst Count
- RNAC 7
- FHTX 5
- Target Price
- RNAC $40.80
- FHTX $16.00
- AVG Volume (30 Days)
- RNAC 107.5K
- FHTX 134.3K
- Earning Date
- RNAC 11-07-2024
- FHTX 11-04-2024
- Dividend Yield
- RNAC N/A
- FHTX N/A
- EPS Growth
- RNAC N/A
- FHTX N/A
- EPS
- RNAC N/A
- FHTX N/A
- Revenue
- RNAC $47,938,000.00
- FHTX $25,515,000.00
- Revenue This Year
- RNAC $69.22
- FHTX N/A
- Revenue Next Year
- RNAC N/A
- FHTX $8.77
- P/E Ratio
- RNAC N/A
- FHTX N/A
- Revenue Growth
- RNAC N/A
- FHTX N/A
- 52 Week Low
- RNAC $11.67
- FHTX $2.70
- 52 Week High
- RNAC $42.60
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- RNAC 39.04
- FHTX 44.69
- Support Level
- RNAC $15.50
- FHTX $8.52
- Resistance Level
- RNAC $22.20
- FHTX $9.33
- Average True Range (ATR)
- RNAC 1.65
- FHTX 0.70
- MACD
- RNAC -0.56
- FHTX 0.00
- Stochastic Oscillator
- RNAC 24.43
- FHTX 28.69
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.